84,691 Shares in AstraZeneca PLC $AZNCF Purchased by L & S Advisors Inc

L & S Advisors Inc bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 84,691 shares of the company’s stock, valued at approximately $14,863,000. AstraZeneca makes up 1.4% of L & S Advisors Inc’s holdings, making the stock its 15th biggest holding.

Other institutional investors have also added to or reduced their stakes in the company. Mascoma Wealth Management LLC acquired a new stake in AstraZeneca during the fourth quarter worth about $46,000. Valley Wealth Managers Inc. acquired a new stake in AstraZeneca during the fourth quarter worth about $144,000. Saranac Partners Ltd acquired a new stake in AstraZeneca during the third quarter worth about $876,000. Hendley & Co. Inc. acquired a new stake in AstraZeneca during the fourth quarter valued at approximately $11,373,000. Finally, Boston Common Asset Management LLC boosted its holdings in AstraZeneca by 5.6% during the third quarter. Boston Common Asset Management LLC now owns 192,589 shares of the company’s stock valued at $28,992,000 after purchasing an additional 10,154 shares in the last quarter. 40.87% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

OTCMKTS AZNCF opened at $187.10 on Friday. The stock’s 50 day moving average is $187.10 and its two-hundred day moving average is $183.70. AstraZeneca PLC has a 1-year low of $122.26 and a 1-year high of $195.00.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.